March Biosciences

Executive Summary

March Biosciences is a clinical-stage cell therapy company developing novel CAR-T approaches for challenging hematological cancers. Its lead candidate, MB-105, targets an undisclosed antigen in a unique target space, leveraging proprietary engineering to enhance safety and efficacy. The company aims to overcome limitations of current CAR-T therapies, such as target escape and on-target off-tumor toxicity. Preclinical data suggest potent anti-tumor activity, and the ongoing Phase 1 trial is evaluating safety and preliminary efficacy in relapsed/refractory patients. With a differentiated platform and a focus on high-unmet-need indications, March Biosciences represents a promising player in the cell therapy landscape.

Upcoming Catalysts (preview)

• Q4 2026Initial Phase 1 safety and efficacy data for MB-10575% success
• Q2 2027Completion of dose escalation and selection of recommended Phase 2 dose80% success